Smoldering Multiple Myeloma (SMM) is a precursor plasma cell disorder characterized by the presence of an M-component concentration equal to or greater than 3 g/dL and/or bone marrow plasma cell infiltration of 10-59%, without any myeloma-defining events. The outcome is heterogeneous, especially regarding progression to active disease such as Multiple Myeloma or other plasma-cell related disorders. The current standard of care is observation, but ongoing and completed research suggests it is possible and straightforward to identify SMM patients at high risk of progression to Multiple Myeloma (50% at 2 years).

This session will feature two clinical cases that highlight the issues involved in determining whether early treatment is the optimal approach for managing this precursor plasma cell disorder and if early treatment is the only way to potentially cure Multiple Myeloma.

Dr. Mateos will discuss the role of early treatment in Smoldering Myeloma as a strategy to cure the disease. She will present evidence supporting the benefits of early intervention and its impact on long-term outcomes.

Dr. Ramasamy will provide a counterpoint to this approach, addressing the costs and toxicities associated with early treatment. He will discuss the potential downsides and argue for a more conservative management approach based on observation.

We look forward to a dynamic and educational session that will provide valuable insights into the management of Smoldering Multiple Myeloma